Discussion: Mycoplasmal Etiology by unknown
DISCUSSION: MYCOPLASMAL ETIOLOGY
DR. LANDY: My comments are directed to Dr. Thomas. I am very interested in
his comments on the effect of live or killed mycoplasma, or their products, on blast
transformation of lymphocyte in tissue culture. If I understood him correctly, these
findings are remarkable in two respects. First, it is a new agent. There was a recent
report in Science, which, if I recall correctly, relates to similar effects of rubella on
human lymphocyte. All this is relevant to Dr. Hildreth's comment on suppression of
the immune response by concurrent viral infection. Second, what I found rather re-
markable in Dr. Thomas's remarks, and I would be grateful if he would amplify them,
is the apparent lack of competitive inhibition for a key receptor site on the lymphocyte.
If these effects are reversible, then I for one find them very difficult to understand or
interpret.
DR. L. THOMAS: I am not sure whether the effects that we have observed are
similar in all respects to those obtainable with rubella because I am not sure that the
rubella experiments quite paralleled ours. I can say the following, though, with re-
spect to reversibility: If the lymphocytes are exposed to mycoplasma, or to the soluble
extract of mycoplasmae obtained by freezing-thawing, there is no response to added
PHA. If the cells are washed, 24 hours later PHA responsiveness remains, or is evi-
dent without the addition of more PHA. Something, launched by PHA, is suppressed
for as long as the mycoplasmae are there, but is still capable of functioning if the
mycoplasma inhibitor is removed.
I don't know what this means. This is just now underway, therefore, I don't know
how it is going to come out. Thus far it looks as though the material will inhibit
lymphocyte responsiveness only for as long as it is present in the medium containing
the lymphocytes. When it is removed, the lymphocytes appear to return to normal.
DR. LANDY: May I ask if there is no evidence of binding to cells?
DR. L. THOMAS: On the contrary, since we can reverse so completely that we
must assume it can't be bound at all.
DR. PHILIP PATERSON: I wanted to ask a question of Dr. Thomas and then
maybe of Dr. Fabricant if I can.
I recall that mycoplasma can be shed for a long time in the sputum of patients with
Mycoplasma pneumoniae, whether or not tetracycline therapy is instituted. I wonder
if the pulmonary secretions lack the mycloplasmacidal tissue factor referred to by
Dr. Thomas. Or, perhaps, is it conceivable that the mycoplasmae inhibit synthesis or
the mammalian tissue factor referred to?
DR. L. THOMAS: I can't answer the question directly. I have assumed, although
we have not approached this in the laboratory, that it is possible that mycoplasmae
shed into the lumen of the bronchial tree are in a position of advantage because they
are not exposed to the products of lysed or destroyed cells.
We also have been interested in the long periods of time over which one can re-
cover mycoplasmae. I have been struck by the rapidity by which mycoplasmae appear
and disappear from some animals as evidenced by attempts to recover them from
homogenates of whole organs such as the brain. For example, Mycoplasma neurolyti-
cum given in tremendous doses intracerebrally to the mouse and rat vanishes within
less than 48 hours, although it may seem to disappear because we are unable to
recover.
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DR. MIDDLETON: I want to inquire about the possibility of neurominidase being
the toxin, or the active material which is toxic in the whole animal and conceivably
also the material which is influencing the lymphocyte transformation reaction.
In partial answer to Dr. Landy's question, if neuroninidase is added to the active
material, a competitive inhibitor in the form of neurominlactose results. This could
be added to determine whether the effect might be abolished.
I would like to mention also, in a preliminary way, that in mixed lymphocyte cul-
tures preincubated with Cholera vibrio neurominidase, there is a diminution in the
amount of tritiated thymidine uptake, suggesting that some surface sugar may be
involved in the recognition process.
DR. L. THOMAS: WVe have tried to study the toxicity of neurominidase as such,
and also of glycosidases, to see whether any of the effects of the neurolyticum toxin
could be imitated. It is a clumsy system to work with, and the materials are toxic.
I do not know whether neurominidase is contained in the mycoplasma strains that
we are using for inhibition of lymphocyte responsiveness. This we plan to explore.
Some strains of M. gallisepticum do not cause erythrocyte aggregation, but upon
treatment with these strains, the erythrocytes become nonreactive to bonafide gal-
lisepticum agglutination. We think this is due to removal of the receptor from the
red blood cell. I suspect that the neurominidase is possessed by some or many strains
of mycoplasma.
DR. MACNAMEE: I concur with Dr. Fabricant's comments concerning the ac-
ceptability of the laboratory rat as a model for pulmonary studies. Unfortunately, this
animal has been rejected for use by many investigators who believe it impossible to
find a colony of rats with normal lungs. It is also their contention that the control
animals exhibit the same lung pathology as those exposed to a lung irritant because
the "normal" rat has a "dirty lung," and little can be done about it.
The rat has no priority for diseased lungs, however it is not impossible to maintain
a colony of laboratory rats with normal lungs. Good sanitary procedures and the same
high standards of colony management as should be employed in the care of all species
will eliminate pulmonary infection from the breeding stock, and thus from the progeny.
It is also to be expected that every effort will be made to establish healthy colonies of
rats, either by elimination of the diseased stock and procurement of healthy animals,
or by establishment of healthy stock, first from gnotobiotic and then pathogen-free
animals. Many experimental pathologists claim that laboratory rats are healthy in
every way excepting the respiratory and that they have never seen a healthy, normal
appearing rat lung. This is quite possible if their source of supply is derived from a
diseased colony. Such claims are difficult to accept; we should be greatly concerned
over the validity of data obtained from so-called healthy rats with diseased lungs,
even when the research objective is not pulmonary in its orientation. It is also pos-
sible that the experimental pathologists fail to recognize that the microscopic ap-
pearance of the normal rat lung is not identical to that of the hamster, rabbit, monkey,
mouse, or other experimental species.
A number of experimentalists are successfully using the rat for studies of chronic
pulmonary disease. Like all other species it is not the ideal model for pulmonary
disease of man. Since it is one of the many animals from which significant results
currently are being obtained, more consideration should be given to the use of the
rat by those researchers who have access to healthy animals.
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DR. PHILIP PATERSON: Dr. Fabricant, you mentioned lesions from E. coli; I
assume you have isolated E. coli from the birds, including the controls, on first passage.
What is the infectivity of those E. coli isolates in subsequent passage for birds without
the ancillary infection with MG or IB? Are the E. coli isolates of the same serotype,
or have they undergone sero-conversion in some way?
DR. FABRICANT: This has not been investigated. We only compared the de-
velopment of lesions with those which occur under field conditions. We started with
a mixture of three serotypes to avoid the possibility that any one serotype might be-
have differently than another. We were interested in evaluating the effect of the other
factors on the E. coli infection which caused the terminal disease under field conditions.
This is not a minor problem, but progress has been slow. Something in the order
of 50 or 60 per cent of the chickens, millions of birds, that are condemned at Federal
processing plants result from this combination of circumstances.
I would like to point out that this is not just a laboratory model. We have since
learned that under field conditions, removing only the M. gallisepticum will markedly
reduce E. coli infections. That is, M. gallisepticum-free birds under field conditions
have an almost negligible incidence of lesions of this sort, as compared to an average
of from one to 10 per cent lesions in MG--infected birds.
DR. PHILIP PATERSON: But it would be important to know whether these E.
coli have any opportunity for serial passage in free birds.
DR. FABRICANT: I don't think anybody has investigated this as yet.
I would like to comment on the question you raised with Dr. Thomas. Maybe we
were lucky as we were using rather crude procedures, but by just taking swab prepara-
tions from M. gallisepticum-infected chicken and turkey brains, we have quite often
succeeded in isolating the organisms. I think possibly you are right to assume that a
whole brain homogenate will contain some inhibitor.
It should be noted that M. gallisepticum will grow in both chickens and eggs in
the presence of tremendously high levels of antibodies.
DR. MUFSON: To date, there is no evidence that mycoplasmae, acting alone or
in concert with other organisms, play an etiological role in human bronchitis or em-
physema. Because these organisms produce chronic respiratory disease in a number
of animal species, it is reasonable to search for them as etiologic agents in human
disease. Animal model systems, unfortunately, suffer from the fact that the organisms
rarely cross species lines. The model presented by Dr. Clyde is important because
M. pneumoniae crosses species lines and produces disease in animals other than man.
I think some obvious experiments might be followed through.
I would like to ask Dr. Clyde if his animals infected with M. pneumoniae develop
either chronic respiratory disease or evidence of chronic respiratory disease over a
long period after post-inoculation, or if he has attempted to superinfect the M. pneu-
moniae-infected animals with virus or bacterium. Also has he attempted to produce
respiratory disease by intranasal inoculation of M. pneumoniae in hamsters previously
inoculated systematically to produce M. pneumoniae antibody?
DR. CLYDE: We haven't done much with the hamster model in terms of studying
chronic pulmonary changes.
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As I illustrated earlier, one can look upon the type of infection produced as a
chronic one. Consider the time that is required to do an experiment like this, and then
think about the average life span of the hamster. The point is that the type of disease
that we see in man runs a much longer course than what is seen in the hamster.
Clinically, at least, we see only the tip of the iceberg. If one considers the incubation
period, the period of clinical disease, the carrier state, the time needed for develop-
ment of immune mechanisms, and elimination mechanisms, a very long span of time
is involved.
DR. MUFSON: Did you attempt to superinfect these M. pneumoniae-infected
animals with a virus or a bacterium?
DR. CLYDE: No, we have not tried this type of experiment.
I would like to make one comment that bears on technique, as mentioned earlier
by Dr. Thomas. This has to do with the efforts at quantitation of mycoplasmae in the
hamster model. At the beginning, it was our feeling that optimal preservation of the
mycoplasmae would occur only if we used as the vehicle a "complete" broth medium
containing 20 per cent horse serum. Thus, we made all dilutions, and ground the lung
tissue, in horse serum broth. We then saw the phenomenon that Dr. Thomas has
mentioned-namely, inhibition of the organisms in the most concentrated samples of
suspension. As one diluted out beyond this 1 to 100 or 1 to 1,000 dilution growth
would then occur. We have learned recently that if normal saline or phosphate buffer,
rather than broth-serum, is used as the vehicle for dilution, no inhibition occurs, at
least in the crude way that this is measured by terminal dilution.
DR. KARZON: I would like to ask Dr. Thomas to extend some of his findings.
He demonstrated that mycoplasma, or some of its products, inhibit blast transforma-
tion, DNA synthesis, and, indeed, RNA synthesis. This can have many theoretical
implications. This same type of inhibition has been involked with measles virus to
explain the inhibition of delayed hypersensitivity of the tuberculin type, for example.
Dr. Thomas, have you been able to show the depression of delayed hypersensitivity
either in man or in an experimental model to accompany mycoplasma infection? Also,
is there any evidence that mycoplasma infection growing locally as it does may de-
crease the local plasma cells? This would be singularly important because the IgA-
producing cells in the pararespiratory region may be depressed by prolonged per-
sistence of mycoplasma, possibly preventing secretory antibody formation to a super-
infection.
DR. L. THOMAS: We have tried to discover whether mycoplasmas can inhibit in
znvo delayed reactivity of PPD in guinea pigs. The results are extremely thin. I
think there is a little suppression, but it is not enough to exclude the alternate pos-
sibility that we are simply swamping these animals with too much antigens.
The guinea pig is not susceptible to mycoplasma infection with any of the strains
that we are using. We have not yet attempted to find out whether the soluble inhibitor
or the whole organism will interfere withe the capillary tube in sitro model for de-
layed reacitivity which David and others in our group have been working with for
some years. So I can't answer that question.
I am unable to say whether local infection by mycoplasmas can depress the emer-
gence or the activity of plasma cells.
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Early on, the most conspicuous, indeed, the only cell reactant in the arteries of
turkeys is the lymphocyte. And it is not until ten days or two weeks later that one
sees large numbers of plasma cells. At that time, the mycoplasmae may have to some
extent been cut off.
DR. AUSTRIAN: Some of Dr. Thomas' comments about mycoplasmae are reminis-
cent of the behavior of influenza viruses. I wonder whether his strains would attach
to human erythrocytes with the result that George Springer showed some years ago,
i.e., the loss of M and M agglutinability.
DR. L. THOMAS: I can't tell you, although human erythrocytes are less readily
agglutinated than turkey, chicken, or mouse erythrocytes.
DR. ABINANTI: I would like to ask Dr. Clyde two questions. The first question
is whether there is validity to the hypothesis that the cold agglutinins seen following
M. pneumoniae infections are anti-lung antibodies. The second question relates to
your thoughts on the hypothesis that the mycoplasma membrane mimics the host cell
membrane and therefore presents the possibility of autoimmune disease.
DR. CLYDE: Those are pretty sticky questions. It is conceivable to me that the
peroxide liberated by M. pneumoniae could have some role in the development of the
pathologic changes in the host. On the other hand, when one thinks about the ready
availability of catalase in so many tissues, it is hard to see that this would have much
impact. And certainly the pathologic changes that we have been able to find in the
animal model don't look much like a direct type of chemical injury.
I don't know personally what to make out of the question of the similarities or
differences between the mycoplasma membrane and host cell membranes. The work
of Barile seems to suggest that some red cell and "I" antigens resemble an antigen
present on some mycoplasma membranes. How this relates again to the basic patho-
genesis for expression of disease, I don't know.
DR. CASS: During this conference there have been repeated examples of the ani-
mal's surroundings participating significantly in the outcome of the study. We must
appreciate that the animal model selected has its unique, inviolate biological character-
istics which are established at the time of conception, and which may vary widely at
any point in time. Superimposed on this is the experimental environment, much dif-
ferent from the ecological situation of, for example, a domestic farm animal. Included
among the environmental factors are a variety of physical (temperature, humidity,
noise, light, etc.) and chemical (urine, ammonia, feces, pesticides, disinfectants, de-
odorants, etc.) factors, all of which are variable and interact with one another and
with the animal to influence the biological characteristics and states of the model. In
addition, experimental manipulation will introduce procedural factors. This then is
the total picture of what might be called the ecology to the laboratory animal.
DR. L. THOMAS: I would like to add one cautionary practical note for the bene-
fit of those who may wish to study the effects of mycoplasma on red cells and their
surface constitutents. The liberation of peroxide by all mycoplasmae is sufficient,
despite the availability in the cells of catalases, to produce methemoglobin-hemoglobin
formation and hemolysis within a very short time. This is an unnerving experience if
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you are looking for delicate changes in cell surface constituents. Unless ways can be
found around it such as the incorporation of excess catalase or peroxidase into the
system, it is necessary to work at 40. None of the studies on the agglutination by M.
gallisepticum utilizing the sialic receptor protein system, have been conducted at 370
because of this hazard.
DR. CATE: Despite the immunological defects that Dr. Thomas has described and
the secondary infections that Dr. Fabricant has described, it is my impression that in
M. pneumoniae infection of humans secondary infection is relatively infrequent as
compared to such infections as caused by the rhinoviruses and the influenza virus.
DR. CLYDE: It is almost as if the mycoplasma infection exerts a protective effect
if you compare critically the incidence of secondary infection following mycoplasma
disease with the others mentioned.
DR. TYLER: I am not very familiar with the rat model, but it seems to me that
there have been numerous descriptions of the vascular component of human em-
physema. I am curious whether the rat model has a vascular component.
DR. L. THOMAS: I am not sure I can help directly, but in the menagerie of pul-
monary lesions that one encounters in rats, which may or may not be due to myco-
plasma infection, angiitis is a very conspicuous element.
I would also like to cast a vote for further studies on acute and chronic pulmonary
disease in the rat which has not been studied well at all. I am not yet sure which of
the several rodent mycoplasmae is responsible, and I don't think it is quite as compli-
cated a situation as we make it out to be. One must be careful of such things as food
inhalation, but rats do have a very satisfactory kind of disease to study if one starts
with fairly clean animals.
DR. KARZON: Perhaps Dr. Fabricant can help with a practical matter.
Because of the species specificity of so many of the mycoplasma organisms, which
ones are now available for study in some of the animals now used-mice. rats, guinea
pigs, hamsters, rabbits, dogs or primates? Also I am interested in Dr. Clyde's ability
to adapt the human strain to hamsters and wonder if that can be done in any of these
other species.
DR. FABRICANT: I don't think there is a direct answer to this. Even with M.
pulmonis, as Dr. Thomas has brought out, the relationships are not clear-cut. This is
going to take intensive investigation. We just don't have all the needed information at
the moment.
It has been a good many years since anybody has put much effort into trying to
identify the mycoplasma flora of the rat. This work was done long ago by Dr. Sabin
and many other workers when techniques were not nearly as good as they are now.
A careful reinvestigation of the mycoplasma flora of the rat would be one of the pre-
liminary indications for this work.
DR. WEISER: Dr. Thomas, when you link lymphocytes to L cells with your
mycoplasma, what happens? Do you find anything like allergenic inhibition?
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DR. L. THOMAS: I can't answer the question because the experiments are in
progress now. We, of course, set it up in order to see whether we would get cell dis-
cretion by lymphocytes; once we did, and three times we did not. It may be that the
mycoplasmae shut off the lymphocytes and thus are unable to function in the cells.
DR. ABINANTI: I would like to come back to the subject of an animal model
system. In all of the discussion so far, no one has mentioned the pig. The pig would
seem an excellent animal for studies of chronic obstructive respiratory disease for the
following reasons: (1) a chronic pneumonitis occurs in nature following mycoplasma
infection; (2) multiple serum and lung puncture specimens could be obtained without
compromising the animals' survival ability; (3) if adequate handling facilities are
available, the pig makes an excellent research animal; and (4) no particular problem
should be encountered in designing equipment for exposing pigs to gases.
DR. FORSYTH: I would like to comment on the possible use of the pig as an
experimental animal model system for virus-induced chronic respiratory disease.
Jennings and Betts have successfully infected pigs with human adenoviruses, produc-
ing bronchopneumonia with destruction of bronchial epithelium. This observation ap-
peared to me to be the basis for an excellent potential animal model system since the
agent involved was a human respiratory pathogen and the histological lesion might be
expected to impair the pulmonary clearance mechanism and cause progressive disease.
DR. KILBURN: I am wondering how one translates from an animal model sys-
tem to man when we know that most of the chronic respiratory disease of man, whether
it be bronchitis or emphysema, or even the infiltrative disease, are basically diseases
of the third or fourth decade and beyond. Who has defined an old guinea pig or an
old rat, and how different is the old guinea pig or old rat from the young rat or
young guinea pig?
Until we can translate this, I think we will have trouble with animal model systems.
We don't find emphysema or bronchitis very commonly in children. even in those with
a genetic defect. Yet I guess that everyone uses fairly young animals.
DR. FABRICANT: This is why I think the rat is such an interesting model. Be-
fore we ever knew anything about the etiology of chronic lesions in the rat-it has
been probably for 30 to 40 years-it was known that old rats characteristically have
chronic pulmonary lesions, usually bronchiectases and pneumonias. This is not seen
to any degree in young rats.
In the rat, a basic study needs to be made of the changes in the physiology and
structure of the respiratory tract during the aging process in the absence of any in-
fectious agents.
DR. KILBURN: Can someone tell me what an old rat is? How many days, weeks,
or months old is an old rat? We know that man's life span is three score and ten. Does
the rat's life span six months, six years?
DR. FREEMAN: I can guess it is about 2X2 to 3 years. We have been dealing
with rats now for about seven years which is considerably longer than the life span
of any rat I know of. We have been working with young rats for the most part and
keep them as long as possible.
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DR. GARETH GREEN: I would like to comment on the timing of our experi-
ments. Although we do see bronchitis and emphysema in the third and fourth decades,
I think we can assume there is a long period of asymptomatic disease, perhaps stretch-
ing back to childhood and perhaps analogous to young animals. As a matter of fact,
there is quite a bit of symptomatic bronchitis in children. It is not presumably genetic
chronic bronchitis, and we don't yet know what happens to these children. The winter
long sniffling and coughing that is so frequent in many children may have considerable
relationship to the later development of chronic lung disease. Therefore, I feel that
studying young animals is not necessarily unrelated to the problems of chronic bron-
chitis and emphysema.
DR. CLYDE: I would like to emphasize what Dr. Green said. Certainly there are
nice models in children of chronic bronchopulmonary disease. Cystic fibrosis is such
an example, as well as the type of chronic bronchitis that develops in the face of some
of the immunologic deficits.
Another point I would like to make has to do with the expression of mycoplasma
disease in children which we feel is quite different from what is seen in adults char-
acteristically. "Characteristically" may be a bad word if you are trying to define what
is typical about atypical pneumonia. The disease as we have seen it in some of the
epidemics studied in our locality consists of a much more subacute or smoldering type
of disease in the child than is seen in the adult. Where the adult may have rather acute
onset of fever, prostration, and signs of pulmonary involvement, the child often does
not. He may present a low-grade fever, show no physical signs whatever, but have
pneumonitis on X-ray. Or he may present a type of illness that persists with a cough
for four to six weeks. This is not unusual in a school-aged child. So there is, I
think, a wide spectrum in clinical expression of this type of disease that does have
some age-related significance.
DR. KLEINERMAN: Getting back to Dr. Kilburn's point concerning the oc-
currence of emphysema lesions in the young for the past several years. we have been
studying this problem in a group of young people who died acutely and traumatically.
We have found that there is a rather remarkable incidence of a small lesion resembling
emphysema in the young group from ages 15 to 44 years. We find these lesions past
the second decade in up to 50 per cent of those that we have studied. These are small
lesions involving less than 50 per cent of the lung parenchyma. Nevertheless it is
there, and we can observe it.
DR. BRAUDE: In examining many strains of mycoplasma for hemadsorption, we
found that the only two exhibiting this property were the Eaton agent and the myco-
plasma associated with bronchiectasis in rats. I think that this analogy between a
naturally occurring human strain and a mycoplasma from a laboratory animal might
indicate that the organisms have a common means of attaching to cells and injuring
tissue, and that rat mycoplasma disease may be a feasible natural model for investi-
gating certain aspects of the pathogenesis of Eaton agent infection.
DR. MONTO: I would like to recall, in support of the use of a rat-like animal for
the study of mycoplasma, that Eaton's original work in isolating the organism was
done on the cotton rat, a model certainly available for mycoplasma studies.
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